Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOCHOLEST LIGHT vs FLAVORED COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
Adjunctive therapy to diet for reduction of elevated LDL cholesterol in primary hypercholesterolemia (Fredrickson Type IIa) in patients who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: adjunct in treatment of hyperthyroidism (binding of thyroxine), pseudomembranous colitis (binding of Clostridioides difficile toxins), and digoxin toxicity
Adjunctive therapy for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: Digoxin toxicity, pseudomembranous colitis, methotrexate toxicity
LOCHOLEST LIGHT is not a recognized drug name. No data available.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Not metabolized; excreted unchanged in feces as the bile acid-resin complex.
Colestipol is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Does not bind to plasma proteins as it is not absorbed.
Apparent volume of distribution is approximately 0.5-0.7 L/kg; extensive distribution into extravascular tissues, including the liver, which is the primary site of action.
Not applicable; minimal systemic absorption (Vd essentially 0).
Oral bioavailability is low (approximately 5-10%) due to extensive first-pass metabolism in the liver and gut wall; food increases absorption slightly (no dosage adjustment required).
Oral bioavailability is <0.05% via absorption; acts locally in GI tract.
No data available.
No specific recommendations; use caution in severe renal impairment due to potential accumulation of inactive ingredients. GFR <30 m L/min: consider alternative agents or reduced dose under clinical monitoring.
No data available.
No specific guidelines for Child-Pugh scores; no expected alterations in pharmacokinetics as drug is not systemically absorbed. Use with caution in severe hepatic impairment due to potential electrolyte disturbances.
No data available.
Not established for children under 18 years; safety and efficacy not determined. In adolescents (≥18 years) use adult dosing titrated to effect with close monitoring.
No data available.
Start at low end of dosing range (5 grams once daily); titrate slowly. Monitor for constipation, electrolyte imbalances, and drug interactions. No specific age-based dose adjustments recommended.
No FDA boxed warning.
Not applicable (no FDA black box warning).
May cause hypertriglyceridemia; monitor triglycerides. Risk of bleeding due to vitamin K deficiency with long-term use. May reduce absorption of fat-soluble vitamins (A, D, E, K). Can cause fecal impaction; use with caution in constipation-prone patients. May bind other drugs; separate administration by at least 4 hours.
Can cause hypertriglyceridemia; caution in patients with pre-existing hypertriglyceridemia. Risk of fat-soluble vitamin deficiency (A, D, E, K) with long-term use. May interfere with absorption of other medications; administer other drugs at least 1 hour before or 4 hours after colestipol. Constipation may worsen hemorrhoids. Use caution in patients with gastrointestinal motility disorders or history of bowel obstruction.
Complete biliary obstruction (ineffective and may cause fecal impaction), hypersensitivity to any component, severe constipation or fecal impaction, hypolipidemic states (e.g., abetalipoproteinemia).
Complete biliary obstruction (contraindicated because ineffective). Hypersensitivity to colestipol or any component of the formulation.
Cholestyramine binds to bile acids and can interfere with absorption of fat-soluble vitamins (A, D, E, K). Patients should consume a diet rich in these vitamins or consider supplementation. High-fiber foods may aid in reducing constipation. Avoid excessive intake of high-fat foods as they may worsen hypertriglyceridemia.
Take with meals to enhance efficacy. Avoid high-fat meals as they reduce binding capacity. Mix with non-carbonated beverages or soft foods; do not take dry. Can be mixed with orange juice without affecting efficacy. May reduce absorption of fat-soluble vitamins; consider vitamin supplementation if long-term therapy.
First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documented human fetal adverse effects. Overall, use only if clearly needed.
Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, use during pregnancy may impair absorption of fat-soluble vitamins (A, D, E, K), potentially affecting fetal development. Trimester-specific risks: First trimester: theoretical risk of vitamin deficiency. Second and third trimesters: risk of vitamin K deficiency leading to neonatal hemorrhage. Overall, the drug is considered low risk due to lack of systemic absorption.
Excretion in human milk unknown. Caution advised. M/P ratio not available.
Colestid is not absorbed systemically, so it is unlikely to be excreted into breast milk. No data on M/P ratio. It is considered compatible with breastfeeding, but caution is advised due to potential interference with maternal absorption of fat-soluble vitamins, which could affect milk composition. Monitor infant for signs of vitamin deficiency.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnancy.
No dose adjustment is required due to lack of systemic absorption. However, ensure adequate supplementation of fat-soluble vitamins (A, D, E, K) and folic acid, as colestipol may reduce their absorption. Administer colestipol and vitamin supplements at least 4–6 hours apart to minimize interaction.
Locholest Light (cholestyramine) is a bile acid sequestrant used for hyperlipidemia. Monitor for decreased absorption of fat-soluble vitamins (A, D, E, K) and consider supplementation. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. May increase triglyceride levels; avoid in patients with hypertriglyceridemia above 400 mg/d L. Can cause constipation; ensure adequate fluid and fiber intake.
Flavored Colestid (colestipol) is a bile acid sequestrant used as adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol. Administer with meals to maximize binding of bile acids. Mix with liquids (water, juice, milk) or soft foods (applesauce, crushed pineapple). Avoid concurrent administration with other medications; give at least 1 hour before or 4 hours after other oral drugs to reduce interference with absorption. Monitor for constipation, which can be severe; increase fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation in long-term therapy.
Take cholestyramine exactly as prescribed, usually mixed with at least 4-6 ounces of fluid.,Do not take the powder dry; always mix with water, juice, or milk to avoid choking.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Report unusual bleeding, bruising, or dark stools as signs of vitamin K deficiency.,This medication may increase triglyceride levels; monitor blood tests as directed.
Take this medication with meals and plenty of water to prevent constipation.,Mix the powder with at least 3-6 ounces of liquid (water, juice, milk) or soft food (applesauce, crushed pineapple) and drink immediately.,Do not take other medications at the same time; take them at least 1 hour before or 4 hours after colestipol.,Common side effects include constipation, bloating, and gas; increase fiber and fluid intake to help.,Contact your doctor if you have severe stomach pain, rectal bleeding, or signs of vitamin deficiency (unusual bruising, bone pain).,Continued adherence to cholesterol-lowering diet and exercise is essential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOCHOLEST LIGHT vs FLAVORED COLESTID, answered by our medical review team.
LOCHOLEST LIGHT is a Bile Acid Sequestrant that works by Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.. FLAVORED COLESTID is a Bile Acid Sequestrant that works by Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOCHOLEST LIGHT and FLAVORED COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOCHOLEST LIGHT is: LOCHOLEST LIGHT is not a recognized drug name. No data available.. The standard adult dose of FLAVORED COLESTID is: 5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOCHOLEST LIGHT and FLAVORED COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOCHOLEST LIGHT is classified as Category C. First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documente. FLAVORED COLESTID is classified as Category C. Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.